Optimer Pharmaceuticals, Inc. (OPTR)
-NasdaqGS 14.97 
0.14(0.93%) May 17, 4:00PM EDT|After Hours
:
14.97 0.00 (0.00%) May 17, 5:03PM EDT
| Prev Close: | 15.11 |
|---|
| Open: | 15.26 |
|---|
| Bid: | 14.25 x 100 |
|---|
| Ask: | 15.40 x 100 |
|---|
| 1y Target Est: | 17.43 |
|---|
| Beta: | 0.75 |
|---|
| Next Earnings Date: | 31-Jul-13 |
|---|
| Day's Range: | 14.74 - 15.48 |
|---|
| 52wk Range: | 8.64 - 16.80 |
|---|
| Volume: | 1,341,138 |
|---|
| Avg Vol (3m): | 1,010,430 |
|---|
| Market Cap: | 729.34M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.21 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- OPTIMER PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Fri, May 17)
- Cubist bid for Optimer before sale process began-sourcesat Reuters(Wed, May 15)
- Cubist bid almost $1 billion for Optimer before sale process: sourcesat Reuters(Wed, May 15)
- Cubist bid almost $1 bln for Optimer before sale process-sourcesat Reuters(Wed, May 15)
- Is AstraZeneca Gearing Up for a Shopping Spree?at Motley Fool(Wed, May 15)
- Markman Hearing A Likely Clearing Event For Cubist - Decision Any Dayat Seeking Alpha(Tue, May 14)
- Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg saystheflyonthewall.com(Mon, May 13)
- AstraZeneca, Cubist, Astellas Said to Make Bids for Optimerat Bloomberg(Mon, May 13)
- Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating OfficerPR Newswire(Mon, May 13)
- 3 Biotech Stocks Spiking With Big Volumeat TheStreet(Mon, May 13)
- OPTIMER PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or PrEDGAR Online(Mon, May 13)
- Investors are Digesting These Healthcare Stock Earnings Insightsat Wall St. Cheat Sheet(Sun, May 12)
- The Best- And Worst-Performing Biotech Stocks, May 3 To May 10at Forbes(Sat, May 11)
- Optimer Pharmaceuticals Misses on the Top and Bottom Linesat Motley Fool(Fri, May 10)
- Why Optimer Pharmaceuticals Shares Sankat Motley Fool(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.91 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.23 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.61 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | -0.40 |
|---|
Business Summary
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and Canada.
View More